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Abstract Propofol (2,6-diisopropylphenol) is one of the safest
and most commonly used anaesthetic agents for intravenous
general anaesthesia. However, in clinical practice, a large inter-
individual variability in response to propofol is observed. To limit
the risk of adverse effects, pharmacogenetic investigations are
recommended. The aim of our study was to verify the impact
of genetic changes c.516G>T in the CYP2B6, c.98T>C in the
UGT1A9 and c.1075A>C in the CYP2C9 genes on the individ-
ual propofol pharmacokinetic profile in the Polish patients un-
dergoing general anaesthesia. Eighty-five patients from the
Department of Anaesthesiology and Intensive Therapy,
Regional Hospital in Poznan, Poland, anaesthetised with
propofol for surgery, were enrolled in the study. We have geno-
typed CYP2B6,UGT1A9 and CYP2C9 polymorphisms with the
use of pyrosequencing. HPLCmeasurements of propofol plasma
concentration were applied for a pharmacokinetic analysis of the
anaesthetic. We identified poor (20), intermediate (42) and rapid
(23) metabolisers of propofol, which constituted 24%, 49% and
27% of the group, respectively. Homozygotes c.516 T/T in the
CYP2B6 gene were statistically more often found in the rapid
metabolisers group (p < 0.05). However, polymorphisms
c.98T>C in the UGT1A9 and c.1075A>C in the CYP2C9 genes
did not affect the pharmacokinetic profile of propofol. The mean
propofol retention time (MRT) correlated with the patient’s body
mass index (BMI) (p < 0.05). From all the analysed changes,
only polymorphism c.516G>T in the CYP2B6 gene and BMI
affect themetabolism rate of propofol andmay play an important
role in the optimisation of propofol anaesthesia.
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Introduction
Propofol is one of the safest and most commonly used anaes-
thetic agents for intravenous general anaesthesia. However, in
clinical practice, a large inter-individual variability, including
adverse reactions, is observed in response to this anaesthetic
(Pasin et al. 2015). Changes between individuals in the phar-
macokinetics of propofol result in differences in the required
dose of anaesthetic needed for efficient general anaesthesia
(Karwacki et al. 2014). This variability is mostly assigned to
the genetic polymorphism of genes coding for enzymes par-
ticipating in the biotransformation pathway of propofol
(Kübler 2005; Mikstacki et al. 2013). The need for gene pro-
filing in anaesthesia has been suggested many times recently
(Landau et al. 2012).
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Propofol is metabolised mainly in the liver by cytochrome
P450 2B6 (CYP2B6) and cytochrome P450 2C9 (CYP2C9)
or by UDP-glucuronosyltransferase 1A9 (UGT1A9)
(Restrepo et al. 2009).
UGT1A9, playing a key role in the biotransformation of
propofol, is responsible for conjugation with glucuronic acid
of around 70% of the metabolised anaesthetic. Because the
enzyme present in the liver, kidney, colon, ovary and testis is
involved in the elimination process of important drugs, such
as irinotecan and flavopiridol, the polymorphism of the
UGT1A9 gene is a subject of pharmacogenetic studies.
Among the most essential variants of theUGT1A9 gene, lead-
ing to decreased enzyme activity, are three known amino acid
changes: p.M33T, p.D256N and p.Y242X. Sequence varia-
tion in codon 33 (c.98T>C, rs72551330, UGT1A9*3) was
identified previously in the Polish population with an allele
C frequency of 0.016 (Zakerska et al. 2013). This substitution
is defined as affecting the pharmacokinetic profile and cata-
lyt ic eff ic iency of binding propofol to UGT1A9
(Korprasertthaworn et al. 2012). An association of this variant
with a reduced glucuronidation level and liver failure in pa-
tients treated with entacapone and irinotecan was observed
(Villeneuve et al. 2003; Martignoni et al. 2005).
CYP2B6 and CYP2C9, catalysing hydroxylation of
propofol in humans, participate in the biotransformation of a
wide range of drugs. A variable expression level of these en-
zymes due to a highly polymorphic nature of genes CYP2B6
and CYP2C9 makes them relevant pharmacogenes. In the
context of propofol response, the most common single nucle-
otide polymorphism (SNP) c.516G>T (p.Q172H, rs3745274)
in exon 4 of the CYP2B6 gene was analysed in several inves-
tigations. The effect of this SNP was proved to be substrate-
specific, and usually led to a disturbed gene expression.
For the CYP2C9 gene, over 65 haplotypes have been de-
scribed, including insertions, deletions and substitutions
(http://www.cypalleles.ki.se/cyp2c9.htm). In global studies,
two non-synonymous changes, p.R144C (c.430C>T,
rs1799853, CYP2C9*2) and p.I359L (c.1075A>C,
rs1057910, CYP2C9*3), determining a poor metabolising
phenotype, are intensively analysed. A substrate-dependent
decrease in the activity of this enzymemay occur. Rare alleles,
CYP2C9*6 (c.818delA, rs933213) resulting in a lack of en-
zyme activity and allele CYP2C9*4 (p.I359T), have been
identified in patients suffering from side effects after phenyt-
oin application (Restrepo et al. 2009).
Awareness of the consequences of important changes in the
UGT1A9, CYP2B6 and CYP2C9 genes in response to propofol
would make it possible to increase the safety of patients under-
going general intravenous anaesthesia. The aim of this studywas
to verify the impact of genetic changes c.516G>T in the
CYP2B6, c.98T>C in the UGT1A9 and c.1075A>C in the
CYP2C9 genes on the individual propofol pharmacokinetic pro-
file in the Polish patients under general anaesthesia.
Materials and methods
Patients
Eighty-five Polish patients (32 women and 53 men) undergo-
ing propofol general anaesthesia (10 mg/mL propofol inject-
able emulsion; Diprivan, AstraZeneca, Macclesfield, UK) for
laryngological surgery in the Department of Anaesthesiology
and Intensive Therapy, Regional Hospital in Poznan, Poland,
were enrolled in this study. All participants gave their in-
formed consent. No history of addiction to alcohol or nicotine
of patients was reported. Patients involved in the study repre-
sented classes I and II of the American Society of
Anesthesiologists (ASA) scale. The study was approved by
the Ethical Committee of the Poznan University of Medical
Sciences, Poznan, Poland (resolution no. 653/09).
Anaesthesia was induced with propofol (2 mg/kg), follow-
ed by a continuous infusion at the rate of 8 mg/kg/h plus
boluses (20–30 mg). Additionally, fentanyl was used to main-
tain anaesthesia. The infusion time, total dose of propofol, sex,
age and body mass index (BMI) were monitored. The charac-
teristics of the patient group are shown in Table 1.
All subjects were screened for plasma propofol concentra-
tion in five time points as follows: at the end of anaesthesia
and 5, 10, 20 and 30 min later. The whole study group was
also genotyped for UGT1A9, CYP2B6 and CYP2C9.
Molecular analysis
Genomic DNA was isolated from the peripheral blood of all
participants using the method with guanidine isothiocyanate
(GTC). Three polymorphic changes, p.Q172H (c.516G>T)
in the CYP2B6, p.M33T (c.98T>C) in the UGT1A9 and
p.I359L (c.1075A>C) in the CYP2C9 genes, were analysed
using pyrosequencing. The amplification and genotyping
conditions of a UGT1A9 gene fragment have been published
previously (Zakerska et al. 2013). The PCR procedure of








Total dose of propofol (mg) Mean 691.4
Range 130–2200
Infusion time (min) Mean 47
Range 10–145
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fragments containing codons 172 of the CYP2B6 and 359 of
the CYP2C9 genes was carried out in a total volume of
30 μL using 0.75 U of FIREPol® DNA Polymerase,
2.5 μL 10× buffer, 2.0 μL dNTP mix (2.5 mM each
dNTP), 1.5 mM MgCl2 solution, 80 ng DNA and 0.2 μM
of each primer (Table 2). Amplification involved 50 cycles at
95 °C for 30 s, 60 °C for 30 s and 72 °C for 60 s. All
reagents were obtained from Solis BioDyne (Tartu,
Estonia). The PCR products were analysed in 1.5 % agarose
gels electrophoresis. Pyrosequencing was performed by the
PSQ™ 96MA system (Qiagen) using PyroMark™ Gold
Q96 Reagents (Qiagen GmbH, Hilden, Germany), as de-
scribed by the manufacturer.
Pharmacokinetic analysis
Propofol concentration in plasma samples was measured
using the HPLC/UV system (P580A; Dionex, Germany)
coupled to a fluorescence detector (RF2000; Dionex,
Germany) detector. As an analytical standard, propofol ob-
tained from Toronto Research Chemicals (Toronto, Canada)
was used. Plasma samples (150 μL) were mixed with 150 μL
of 2 M trichloroacetic acid (TCA) and certifugated at 10,000
× g for 10min. An aliquot of the supernatant was injected onto
an analytical C18 reversed-phase column (Hypersil GOLD,
250 mm× 4.6 mm× 5 μm, Germany) maintained at 30 °C.
The mobile phase constituted 0.6 % (v/v) orthophosphoric (V)
acid and acetonitrile (50:50) at a flow rate of 1.0 ml/min. The
elution profiles of propofol were monitored fluorometrically
at an excitation wavelength of 270 nm and an emission wave-
length of 310 nm. Plasma concentrations of propofol were
determined by Chromeleon software version 6.80 (Dionex,
Germany). For each analysis, the RSD (percentage of relative
standard deviation) was calculated and for the HPLC/UVand
fluorescence method, it was below 2.5 %. All samples were
analysed in duplicate.
As the pharmacokinetic parameter, the mean retention time
(MRT) was calculated for each patient using PKSolver soft-
ware (Zhang et al. 2010). Observed MRT values were
assigned to a percentile rank for a score of 25 and 75.
Statistical analysis
All correlation analyses were performed using Student’s t-test
for Pearson’s linear correlation coefficient, whereas correlation
between metabolic profiles and genetic variants was proved
using the Chi-squared and Fisher’s tests. The value indicating
statistical significance was set at p ≤ 0.05. All calculations were
performed using STATISTICA 12.0 software (StatSoft).
Results
A total of 85 individuals were successfully screened for ge-
netic variants p.Q172H (c.516G>T) in the CYP2B6, p.M33T
(c.98T>C) in the UGT1A9 and p.I359L (c.1075A>C) in the
CYP2C9 genes, using pyrosequencing.
The results showed that allele CYP2B6*9 (c.516T) was
present in the study group with a frequency of 18 %, while
the frequencies of alleles UGT1A9*3 (c.98C) and CYP2C9*3
(c.1075C) were 2% and 4.7%, respectively.
Based on the plasma propofol concentration in five time
points within 30 min after stopping anaesthetic infusion and
on clinical data, the MRT was calculated for each patient
(Table 3). We decided to use this independent pharmacokinet-
ic parameter due to the proved high correlation and lack of
statistically significant difference between MRT and t1/2. In
our studied patients group, the MRT of propofol was in the
range of 8–504 min. Using percentile rank, we identified poor
(20), intermediate (42) and rapid (23) metabolisers of
propofol, which constituted 24 %, 49 % and 27 % of the
group, respectively (Fig. 1).
On the basis of the Chi-squared and Fischer’s tests, we ob-
served that homozygotes c.516T/Twere statistically more often
present in the rapid metabolisers group (p < 0.05) (Table 4).
Furthermore, propofol MRT was correlated with the patient’s
BMI (p < 0.05). The MRT was significantly longer in the case
of individuals with a higher BMI. Moreover, we have observed
that infusion time determines the MRT (p < 0.05). However, we
did not report a correlation between Cmax and the MRT
(p > 0.05). We also did not find the patient’s age to affect the
Table 2 Primers used for the amplification and pyrosequencing of the CYP2B6 and CYP2C9 genes
Direction Primer name Sequence Product length
Amplification Forward (*) CYP2B6_Q172Hf 5′-CCTGCTGCTTCTTCCTAGGG-3′ 83 bp
Reverse CYP2B6_Q172Hr 5′-GACGATGGAGCAGATGATGTTG-3′
Forward (*) CYP2C9_I359Lf 5′-ATGCAAGACAGGAGCCACATG-3′ 181 bp
Reverse CYP2C9_I359Lr 5′-GGGACTTCGAAAACATGGAGTTG-3′
Pyrosequencing Reverse CYP2B6_Q172Hseq 5′-TGATGTTGGCGGTAAT-3′
Reverse CYP2C9_I359Lseq 5′-TGGGGAGAAGGTCAA-3′
(*) = primers labelled with biotin
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Table 3 Summary of the pharmacokinetic and genetic data




MRT (min) CYP2C9 c.1075A>C CYP2B6 c.516G>T UGT1A9 c.98T>C
1 M 46 29.8 300 65 49.8 AA GT TT
2 F 53 24.1 200 35 21.7 AA GG TT
3 M 52 30.9 500 10 178.7 AA GG TT
4 M 50 24.5 500 89 65.2 AC GG TT
5 M 37 24.7 700 59 35.8 AA GG TT
6 F 39 20.1 240 23 44 AA GT TT
7 F 56 37.2 130 14 10.5 AA GG TT
8 F 30 29.8 500 35 27.6 AA GG TT
9 M 30 25.8 600 33 37.9 AA GG TT
10 M 52 27.8 450 36 158.4 AA GG TT
11 M 31 23.6 360 22 47.5 AA GG TT
12 M 47 31.6 400 25 34 AA GG TT
13 M 51 44.8 430 23 37.3 AA GG TT
14 M 52 26.9 290 14 37.2 AA GT TT
15 F 53 31.3 570 45 98.4 AA GG TT
16 M 37 27.8 300 15 70.8 AA GT TT
17 M 51 26.3 550 49 48.3 AA GG TT
18 M 53 31.2 560 65 40.3 AC GT TT
19 F 49 37.0 400 24 467 AA GG TT
20 M 49 27.8 650 43 55.3 AA GT CT
21 F 48 23.5 350 18 25.9 AA GG TT
22 M 48 22.2 540 55 74 AA GG TT
23 M 52 20.9 300 20 33.8 AA GG TT
24 M 31 26.6 340 18 41.9 AA GG TT
25 F 32 21.3 340 22 54.7 AA GT TT
26 F 53 24.7 370 16 62.1 AA GG TT
27 F 52 23.1 330 13 59.5 AA GG TT
28 M 53 29.1 260 40 48.2 AA GG TT
29 M 49 30.7 500 25 28 AA GT TT
30 M 48 26.8 350 35 58 AA GT TT
31 M 52 22.9 430 15 15.8 AA GT TT
32 F 31 19.2 810 87 151 AA GG TT
33 M 51 30.0 780 45 29.2 AA GG TT
34 F 53 22.7 410 30 16.8 AA GG TT
35 M 35 35.2 840 53 198.9 AA GG TT
36 M 51 29.4 430 15 40.9 AA GT TT
37 F 46 24.8 650 87 43.8 AA GG TT
38 F 34 32.5 790 63 44.5 AA GG TT
39 M 48 26.2 310 33 19.4 AA GT TT
40 M 42 25.8 1150 67 106.5 AA GG TT
41 F 56 30.9 1230 108 92.9 AA GG TT
42 M 45 27.2 450 13 60.2 AA GG TT
43 M 44 26.3 360 10 82.5 AA GT TT
44 M 35 23.1 420 14 74.9 AA GG CT
45 M 41 29.6 700 18 108.5 AA GT CT
46 F 49 28.7 850 66 359 AA GG TT
47 F 53 29.4 600 25 149.7 AA GT TT
48 F 52 20.4 280 13 27.5 AA GG TT
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pharmacokinetic marker MRT (p > 0.05). The infusion time did
not influence the Cmax value (p > 0.05).
Discussion
Understanding the factors, especially genetic polymorphism,
that influence the required personalised dose of propofol in gen-
eral anaesthesia was the goal of the present study. Justification
for our investigation was provided by ambiguous literature data
concerning the participation of CYP2B6 andUGT1A9 polymor-
phisms in propofol metabolism. We have analysed the plasma
pharmacokinetic profile of propofol in 85 patients after a stopped
infusion of anaesthetic with an average dose of 2.5 mg/kg. As a
parameter describing the pharmacokinetics in each patient, the
MRT was finally calculated. A high inter-individual variability
of the MRT has allowed for the identification of poor, interme-
diate and rapid metabolisers (Fig. 1).
Table 3 (continued)




MRT (min) CYP2C9 c.1075A>C CYP2B6 c.516G>T UGT1A9 c.98T>C
49 M 38 27.8 570 15 8.4 AC GG TT
50 M 52 25.5 1160 89 128.7 AA GG TT
51 F 32 32.5 1340 142 208.3 AA GG TT
52 M 31 29.4 1150 63 379.9 AA GG TT
53 M 49 30.8 1300 63 100.7 AC GT CT
54 M 53 27.8 1892 132 202.6 AA GG TT
55 F 46 20.8 930 80 191.7 AA GT TT
56 F 45 29.4 1770 145 113.3 AA GG TT
57 F 36 25.9 1000 102 95.2 AA GG TT
58 M 50 39.5 1500 106 58.6 AA GT TT
59 M 31 26.5 550 45 29.2 AA GT TT
60 M 52 22.5 470 13 25 AA TT TT
61 M 52 27.5 900 24 32.4 AA GG TT
62 F 50 24.3 1840 136 70.8 AC GG TT
63 M 47 23.0 2200 113 169.9 AA GG TT
64 F 32 22.1 1350 118 61.2 AA GT TT
65 M 45 21.3 480 35 19.7 AC TT TT
66 F 46 37.0 200 18 23.3 AC GG TT
67 F 32 23.2 440 40 43.2 AA GG TT
68 M 38 29.0 1050 55 28.2 AC GT TT
69 M 52 29.8 420 11 29.1 AA GT TT
70 F 33 21.2 700 45 25.4 AA GG TT
71 M 31 28.8 900 45 393.6 AA GG TT
72 M 55 20.7 300 15 28.8 AA TT TT
73 M 43 26.8 1050 80 41.8 AA GG TT
74 M 32 22.4 1340 60 38.7 AA GG TT
75 F 33 23.0 270 15 28.5 AA GG TT
76 F 35 22.0 1600 95 58.9 AA GT TT
77 M 34 20.1 810 63 40.6 AA GT TT
78 M 32 25.2 830 65 54.9 AA GG TT
79 M 49 26.6 1200 67 116.6 AA GG TT
80 F 49 28.3 400 17 14.2 AA GG TT
81 F 38 27.7 500 13 37.8 AA GT TT
82 M 45 21.1 250 10 8 AA GG TT
83 M 43 29.4 320 13 8.2 AA GG TT
84 F 46 28.9 240 13 30.6 AA GG TT
85 M 54 34.7 1750 89 504.1 AA GG TT
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Analysis of the genotype distribution (for positions
c.516 in the CYP2B6, c.98 in the UGT1A9 and c.1075
in the CYP2C9 genes) in all pharmacokinetic profiles
showed that only the change c.516G>T correlates with
the propofol biotransformation rate. Homozygotes
c.516T/T were statistically more often identified in
rapid-metabolising individuals.
Our results confirm the significance of this non-
synonymous substitution c.516G>T of the CYP2B6 gene in
the propofol metabolic rate and further dosing, which was
proved in several previous studies (Kansaku et al. 2011;
Mastrogianni et al. 2014; Mourão et al. 2016). Kansaku
et al. (2011) has proved this change as a genetic factor deter-
mining the pharmacokinetics and pharmacodynamics of
propofol. They correlated a high maximum blood concentra-
tion (Cmax) of anaesthetic with genotype c.516T/T. It may
suggest, in contrast to our study, a poor metabolism of
propofol. This sequence variation c.516G>Twas also the sub-
ject of pharmacokinetic research on a group of Greek women.
Allele c.516T determined a high blood level of propofol, and
its frequency was 29.5% (Mastrogianni et al. 2014). A recent
study conducted by Mourão et al. (2016) shared the
conclusions formulated by Kansaku et al. (2011) and
Mastrogianni et al. (2014), suggesting that allele c.516T de-
termines a lower dose of propofol administered to patients
undergoing intravenous general anaesthesia.
On the other hand, Iohom et al. (2007) was the first to
suggest an important role of the CYP2B6 gene in the individ-
ual pharmacokinetic and pharmacodynamic profiles of
propofol. However, they did not demonstrate a correlation
between change p.Q172H and clearance of propofol. Similar
conclusions were reached in studies performed by Khan et al.
(2014); none of the analysed polymorphisms inCYP2B6were
associated with a propofol response. Also, Loryan et al.
(2012) did not prove a significant linkage between CYP2B6
and UGT1A9 allelic variants and blood propofol concentra-
tion. As they explained, for some of the rare genetic polymor-
phisms, the study group size was probably too small.
Among the clinical parameters collected in our study, only
BMI was significantly correlated with the pharmacokinetic
profiles of propofol. A longer retention time observed in pa-
tients with higher BMI explains the lipophilic nature of the
anaesthetic (Lotia and Bellamy 2008). However, we did not
confirm the conclusion propounded by Loryan et al. (2012)
concerning the impact of sex on propofol metabolism.
The analysed allele CYP2C9*3 (p.I359L), although it is
known as being associated with altered enzyme activity, did
not have a significant effect on the biotransformation rate of
propofol in our study group. We demonstrated this allele fre-
quency of 4.7 %, which corresponds to the range reported in
Caucasians. Global studies proved the allele CYP2C9*3 to be
correlated with the overdose risk of warfarin and phenytoin
(Lindh et al. 2009). Because, so far, there are no data regarding
the role of p.I359L change in the CYP2C9 gene in propofol
metabolism in anaesthetised patients, it is difficult to discuss
the outcome. Certainly, an important explanation for our re-
sults may constitute suggested substrate dependence of the
CYP2C9 polymorphism.
Table 4 Comparison of
genotypes distribution among the
patients group with different
pharmacokinetic profiles







n % n % n %
CYP2C9 c.1075A>C (p.Ile359Leu) AA 18 90 39 93 20 87 0.99
AC 2 10 3 7 3 13
CC 0 0 0 0 0 0
CYP2B6 c.516G>T (p.Gln172His) GG 16 80 27 64 14 61 0.03*
GT 4 20 15 36 6 26
TT 0 0 0 0 3 13
UGT1A9 c.98T>C (p.Met33Thr) TT 18 90 40 95 23 100 0.35
TC 2 10 2 5 0 0
CC 0 0 0 0 0 0
*Statistically significant
Fig. 1 Characteristics of the propofol metabolisers group with mean
retention time and standard deviation
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The effect of theCYP2B6 p.Q172H change on the propofol
pharmacokinetic profile reported in the available studies is not
fully elucidated. Nevertheless, CYP2B6 plays an important
role in the biotransformation process of this anaesthetic by
the hydroxylation pathway. Possibly, in our study group,
glucuronidation may be the main reaction in anaesthetic me-
tabolism, which would minimise a significant influence of
CYP2B6 gene polymorphism in the propofol response. On
the other hand, there are certain differences between parame-
ters in our study and opposed research performed by Kansaku
et al. (2011). The average age of patients, as well as the infu-
sion time of propofol, was higher in the Japanese investigation
(65 years; an average of 250 min), which may partly explain
the significant divergences in the obtained results. Moreover,
the analysis time of propofol clearance in our research was
limited to the first 30 min after the end of propofol infusion,
while in the Japanese study, it reached 60 min. A clearer dem-
onstration of the influence of the CYP2B6 c.516G>Tmutation
on propofol concentration in patient plasma would probably
be possible with the use of the determination of propofol’s
metabolites; for example, propofol glucuronide and 4-
hydroxypropofol. Additionally, the low frequency of the
c.516G>T variant of the CYP2B6 gene may be a source of
discrepancies between the studies. Kansaku et al. (2011)
found two patients as c.516T homozygotes (of the group of
61 patients) and classified them as poor metabolisers, whereas
in our study, three patients were identified as homozygotes
TT; however, they were all classified as rapid metabolisers.
The statistical analysis has shown the significant correlation of
this genotype with a high rate of propofol metabolism.
We can conclude that polymorphism c.516G>T in the
CYP2B6 gene and BMI affect the metabolism rate of propofol.
Our results constitute an inspiration for further extensive stud-
ies including metabolites measurements and larger groups of
patients. It is suggested that there are more candidate genes as
genetic determinants of individual propofol response, such as
genes coding for transporters and receptor proteins (Iohom
et al. 2007). By using a valuable tool of molecular biology,
high-throughput sequencing techniques, which enable effi-
cient and deep multi-gene analysis, it seems possible to be
able to deliver to clinicians the outline for optimal anaesthesia
with propofol to avoid the risk of adverse reactions (Pareek
et al. 2011).
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